NCT06642220View on ClinicalTrials.gov

Ablative Radioembolization of Renal Cell Carcinoma Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2032

Conditions
Renal Cell Carcinoma (RCC)Radioembolization
Interventions
DEVICE

Y-90 Selective Internal Radiation Therapy (SIRT)

Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.

Trial Locations (1)

N6A 5W9

RECRUITING

London Health Sciences Centre - Victoria Hospital, London

Sponsors
All Listed Sponsors
collaborator

Boston Scientific Corporation

INDUSTRY

lead

Derek W. Cool

OTHER